IP Library › Granted Patent US 11,098,297
Granted Patent B2
US 11,098,297 · App. 16/544,452 · Granted Aug 24, 2021

Engineered Cas9 nucleases

Inventors: Barrett Ethan Steinberg (Cambridge, MA); Derek Cerchione (Cambridge, MA)
Assignee: Editas Medicine, Inc.
C12N9/22C12N15/102C12N15/11C12N2310/20C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,098,297
App. No.
16/544,452
Granted
Aug 24, 2021
Kind
B2
Abstract

The present disclosure relates to Cas9 nuclease variants and methods of producing and using such variants.

Claims (15)

1. A method of modifying a cell, the method comprising administering to the cell:

(i) a polypeptide having nuclease activity and comprising an amino acid sequence having at least 90% identity to SEQ ID NO:13, wherein the polypeptide comprises an amino acid substitution at two or more of the following positions of SEQ ID NO:13: D23, T67, Y128, and D1251; and

(ii) a guide nucleic acid.

2. The method of claim 1 , wherein the guide nucleic acid is a guide RNA.

3. The method of claim 1 , wherein the cell comprises a target sequence and an off-target sequence, and a rate of off-target editing of the off-target sequence by the polypeptide is less than an observed rate of off-target editing of the off-target sequence by a control polypeptide comprising SEQ ID NO: 13.

4. The method of claim 3 , wherein the rate of off-target editing by the polypeptide is about 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, or 80% less than the off-target editing of the control polypeptide.

5. The method of claim 3 , wherein the rate of off-target editing is measured by assessing a level of indels at the off-target sequence.

6. The method of claim 1 , wherein the cell is modified using a ribonucleoprotein (RNP) complex comprising the polypeptide and the guide nucleic acid.

7. The method of claim 1 , wherein the polypeptide comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 13.

8. The method of claim 1 , wherein the polypeptide comprises an amino acid sequence having at least 99% identity to SEQ ID NO: 13.

9. The method of claim 1 , wherein the polypeptide comprises an amino acid substitution at three or more of the following positions of SEQ ID NO: 13: D23, T67, Y128, and D1251.

10. The method of claim 1 , wherein the polypeptide comprises an amino acid substitution at all four of the following positions of SEQ ID NO: 13: D23, T67, Y128, and D1251.

11. The method of claim 1 , wherein the polypeptide comprises two or more of the following amino acid substitutions relative to SEQ ID NO:13: D23A, T67L, Y128V and D1251G.

12. The method of claim 1 , wherein the polypeptide comprises three or more of the following amino acid substitutions relative to SEQ ID NO:13: D23A, T67L, Y128V and D1251G.

13. The method of claim 1 , wherein the polypeptide comprises the four following amino acid substitutions relative to SEQ ID NO:13: D23A, T67L, Y128V and D1251G.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2019
From: STEINBERG, BARRETT ETHAN; CERCHIONE, DEREK
To: EDITAS MEDICINE, INC.
Reel/Frame 050933/0386 →
Continuity (4)
Division 16003967 · Jun 8, 2018
Provisional Application 62665388 · May 1, 2018
Provisional Application 62517811 · Jun 9, 2017
Related Publication 20200056164A1 · Feb 20, 2020
Cited By (2)
US 12,201,699 US 12,297,466